Biotech Investment Strategies: The 'Fundamental Floor' Thesis

Executive Summary

This report details the evolution of a high-probability trading strategy for clinical-stage biotechnology stocks. Moving beyond simple binary bets on FDA outcomes, we developed a "Fundamental Floor" methodology.

This approach seeks to identify companies trading near their liquidation value (Cash or Book Value per Share) to execute Cash-Secured Puts (CSP) or Long Stock positions. The goal is to acquire undervalued assets with a built-in margin of safety, or to generate income from high implied volatility while minimizing the risk of permanent capital loss.

The Thesis: Value-Driven Volatility Trading

Biotech stocks often exhibit extreme Implied Volatility (IV) ahead of binary events like PDUFA dates. Instead of gambling on the outcome, we use this volatility to our advantage by defining a "Floor Price."

The Core Equation

Fundamental Floor ≈ (Total Cash + Cash Equivalents) / Shares Outstanding

Strategy: Sell Puts at a strike price where the Effective Cost Basis is roughly equal to this Cash Floor.

Why it works: If the binary event fails (FDA Rejection), the stock price tends to collapse towards its cash value. By selling puts at this level, we are effectively placing a limit order to buy the company's pipeline and IP for "free," paying only for the cash on the books.

Case Studies & Trade Execution

1. Biohaven (BHVN): The "Goldilocks" Trade

Scenario: Approaching PDUFA for Troriluzole (SCA) in Q4 2025.

Analysis: Initial idea to sell $7.50 puts was deemed too risky (breakeven $6.50) vs. historical drops. We identified a Cash Per Share of ~$3.83.

The Winning Trade:

Action: Sell $5.00 Strike Puts.
Breakeven: ~$4.50.
Rationale: The breakeven is nearly aligned with the cash floor. Assignment would result in acquiring a diverse pipeline at a deep value.
Outcome Plan: "The Wheel" strategy—if assigned, sell covered calls to lower basis.

2. Capricor (CAPR): Stress-Testing the Floor

Scenario: Sold $2.50 Strike Puts (Vega play). Stock crashed ~20% on "manufacturing data" news instead of clinical data.

Lessons Learned:

The "Sell the News" Effect: Even positive but "boring" news can cause a crash as speculative premium evaporates.
Floor Resilience: Despite the drop to ~$4.67, the position remained safe because the Book Value floor is ~$2.30. The $2.50 strike provided a massive cushion against market tantrums.
Verdict: Hold. The fundamental thesis (assets > strike) remains intact.

3. Lantern Pharma (LTRN): The Liquidity Trap

Scenario: Stock trading near 52-week low ($2.55) with Cash Per Share ~$1.47. Ideal setup for a floor trade.

Critical Failure Point: Option Illiquidity.

Observation: Options chains showed zero bids and massive spreads ($0.70 Bid / $3.40 Ask). Execution of a CSP was impossible.

Adjustment: Pivot to Long Stock. When options are broken, buying shares at the floor is the only viable execution.

4. Agios (AGIO): The High-Risk "Anti-Pattern"

Scenario: Major catalysts (PDUFA + Phase 3 Data). High IV (93rd percentile).

Why We Avoided It:

Price: ~$40.67
Floor (Cash/Book): ~$20.00 - $22.00
Risk: The stock is trading at a 100% premium to its floor. A failure would result in a 50% collapse. Selling puts here is "picking up pennies in front of a steamroller."

Comparative Performance Analysis (Sept - Dec 2025)

Visualizing the price action of our thesis candidates relative to the "Fundamental Floor." Note the divergence in volatility profiles.

Future Methodology: Automated Analysis Workflow

To scale this strategy, we designed a Python & Vertex AI workflow to screen 800+ biotech companies:

Ingestion: Aggregate PDUFA dates and merge with yfinance market data.
The "Floor" Filter: Automatically calculate (Price - Cash_Per_Share). Filter for stocks trading < 20% above cash.
Liquidity Check: Programmatically check Option Open Interest > 500 to avoid the "LTRN Trap."
AI Analysis: Use Vertex AI (Gemini) to parse recent news for hidden risks (lawsuits, debt covenants) that simple data might miss.